Monafox (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Monafox, is a fluoroquinolone antibiotic presented as an ophthalmic solution for ocular use. It treats bacterial infections of the eye such as conjunctivitis and keratitis in adult patients.

GNH USA supplies Monafox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monafox is a fluoroquinolone antibiotic indicated for bacterial infections of the eye. - Bacterial conjunctivitis: reduces bacterial load and resolves redness and discharge. - Bacterial keratitis: eradicates causative organisms and promotes corneal healing. - Other ocular bacterial infections: treats infections of the eyelid, sclera or intra‑ocular structures caused by susceptible bacteria.

Adverse reactions may occur with ocular use of Monafox.

Common Side Effects: - Transient eye irritation or burning sensation. - Redness of the conjunctiva. - Temporary blurred vision. - Mild itching or foreign‑body sensation. - Mild tearing.

Serious or Rare Side Effects: - Corneal ulceration or perforation. - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Persistent or worsening eye pain. - Vision loss. - Development of resistant bacterial strains.

Before using Monafox, consider the following precautions. - Allergic history: avoid if known hypersensitivity to fluoroquinolones or any component of the formulation. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Corneal epithelial defects: use with caution; monitor for delayed healing. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk. - Pediatric use: safety and efficacy not established; use only under specialist guidance. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Monafox may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Systemic fluoroquinolones: concurrent use may increase risk of tendon rupture or QT prolongation. - Anticholinergic eye drops: may reduce ocular absorption of moxifloxacin.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: monitor for delayed wound healing. - Corticosteroid eye preparations: may mask signs of infection; assess regularly. - Antacids containing aluminum or magnesium: if systemic exposure occurs, may affect absorption; separate administration by at least 2 hours.